Hengrui Medicine Gets China Approval for Multiple Drug Trials
Published on 11/28/2025 at 02:55 am GMT
MT Newswires
Share
Share
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.45 CNY | +0.24% |
|
+1.70% | -3.56% |
| 02-09 | Jiangsu Hengrui Medicine Gets Breakthrough Therapy Designation for Cancer Drug | MT |
| 02-06 | Hengrui Pharmaceuticals' Gout Drug Application Accepted by Regulators | MT |
Employees
20,238
Sector
Pharmaceuticals
Calendar
Trader
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
AA
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
57.45CNY
Average target price
82.91CNY
Spread / Average Target
+44.32%
Quarterly revenue - Rate of surprise
- Stock Market
- Stock Market News
- Hengrui Medicine Gets China Approval for Multiple Drug Trials
Select your edition
All financial news and data tailored to specific country editions
